Table 3.
Association between exposure to strong CYP450 2C19 inhibiting proton pump inhibitor* and vascular/mortality in patients taking clopidogrel and aspirin
| Exposure† | No of patients | Median follow-up (days) | No of events (all cause mortality or incident myocardial infarction) | Hazard ratio (95% CI) | |
|---|---|---|---|---|---|
| Crude | Fully adjusted‡ | ||||
| Primary outcome | |||||
| All cause mortality or incident myocardial infarction: | |||||
| No strong PPI | 17 405 | 359 | 1414 | — | — |
| Strong PPI | 11 910 | 292 | 1346 | 1.43 (1.33 to 1.54) | 1.39 (1.29 to 1.50) |
| Secondary outcomes | |||||
| All cause mortality: | |||||
| No strong PPI | 17 425 | 367 | 1116 | — | — |
| Strong PPI | 12 012 | 299 | 1112 | 1.45 (1.34 to 1.58) | 1.43 (1.31 to 1.56) |
| Incident myocardial infarction: | |||||
| No strong PPI | 17 405 | 359 | 391 | — | — |
| Strong PPI | 11 910 | 292 | 343 | 1.37 (1.20 to 1.60) | 1.29 (1.12 to 1.49) |
| Vascular mortality: | |||||
| No strong PPI | 17 425 | 367 | 655 | — | — |
| Strong PPIs | 12 012 | 299 | 571 | 1.27 (1.13 to 1.42) | 1.28 (1.15 to 1.44) |
| Non-vascular mortality: | |||||
| No strong PPI | 17 425 | 367 | 461 | — | — |
| Strong PPI | 12 012 | 299 | 541 | 1.72 (1.52 to 1.95) | 1.71 (1.51 to 1.94) |
*Omeprazole, esomeprazole, lansoprazole.
†Captures whether patients were ever counted in this exposure group during follow-up.
‡Adjusted for age, sex, BMI, smoking, alcohol, diabetes, peripheral vascular disease, coronary heart disease, ischaemic stroke, cancer.